TD Cowen Downgrades Soleno Therapeutics to Hold, Lowers Price Target to $53

Benzinga Newsdesk www.benzinga.com Negative 89.9%

Neg 89.9% Neu 0% Pos 0%

TD Cowen analyst Tyler Van Buren downgrades Soleno Therapeutics (NASDAQ:SLNO) from Buy to Hold and lowers the price target from $85 to $53.